Comparing the current results to its competitors, Brainsway Ltd reported Revenue increase in the 4 quarter 2025 by 27.33 % year on year. The sales growth was above Brainsway Ltd 's competitors' average revenue growth of 10.48 %, achieved in the same quarter.
Brainsway Ltd Net Income in the 4 quarter 2025 grew year on year by 159.33%, while most of its competitors have experienced a contraction in net income by -7.1 %.
Brainsway Ltd 's Comment on Competition and Industry Peers
The company operates in a competitive environment with competition from existing treatment options, Traditional TMS competitors, and other stimulation products. The industry is marked by rapid technological changes, new product and treatment protocol introductions and enhancements, price competition, and evolving industry standards. Success requires anticipating changes in technology, market demand, and physician practices to develop, obtain clearance or approval for, and introduce new and enhanced technologies and treatment protocols in a timely and cost-effective manner.
November 20, 2024
: Emerging evidence suggests that Deep Transcranial Magnetic Stimulation (Deep TMS) may offer a promising alternative for managing pain symptoms, particularly in patients with comorbid mental health disorders. Recent feasibility data released by BrainsWay Ltd (NASDAQ: BWAY) reveals significant reductions in pain, anxiety, and depression symptoms associated with the treatment. This article reviews the implications of these findings for clinical practice and future research. Chronic pain and mental health disorders, such as anxiety and depression, frequently coexist, leading to a complex clinical scenario that complicates treatment strategies. Conventional interventions typically target either chronic pain ...
June 17, 2024
BrainsWay Ltd., a renowned global leader in noninvasive neurostimulation therapies for mental health disorders, has recently announced its strategic entry into the Canadian market. The company has signed an exclusive multi-year distribution agreement, solidifying its presence in Canada and further expanding its global imprint. Through this partnership, BrainsWay s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) system will reach a wider audience in Canada, catering to both acute hospital and non-acute healthcare sectors.The distribution agreement is set to facilitate the deployment of BrainsWay s innovative technology across Canada, thanks to a specialty distributor armed with a team of over 35...
April 4, 2024
In a groundbreaking publication, BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has revealed the potential of their Deep Transcranial Magnetic Stimulation (Deep TMS) technology in treating Parkinson s disease. Clinical data from multiple trials has highlighted significant improvements in both motor and non-motor symptoms among patients. The company has also announced the expansion of Deep TMS availability in South Korea, further solidifying their commitment to providing innovative therapeutic solutions.Clinical Data Demonstrates Positive Outcomes:Researchers have long explored the potential of noninvasive neurostimulation techniques in allevia...
December 7, 2023
BrainsWay Announces Expansion of Deep TMS Technology in South Korea: Bolstering Mental Health Treatment Options In a significant move towards advancing mental health treatments, BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments, has announced the expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in South Korea. With recent sales contributing to its growing momentum, BrainsWay s installed base in the country is set to reach over 20 Deep TMS systems. This expansion marks a notable step forward in providing effective and advanced healthcare solutions for individuals battling mental health disorders in South Korea. Deep TMS is a tr...
Electrocore Inc operates on a business model that focuses on developing and commercializing innovative neuromodulation therapies. They utilize non-invasive vagus nerve stimulation (nVNS) to offer patients drug-free solutions for various medical conditions. The company's approach involves leveraging their understanding of the human body's electrochemical signaling system to provide targeted and effective treatments across multiple therapeutic areas.
Neuronetics Inc is a medical device company focused on developing and commercializing non-invasive brain stimulation therapies for psychiatric disorders. Their business model primarily revolves around manufacturing and selling their flagship product, the NeuroStar Advanced Therapy System, which is used for the treatment of major depressive disorder. They generate revenue through the device sales, along with providing support services and maintenance to the healthcare facilities implementing their technology.
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
Electromedical Technologies Inc's business model revolves around the development and commercialization of innovative medical devices. The company focuses on creating and selling safe, non-invasive therapeutic devices that utilize bioelectric technology to address various medical conditions. Through its comprehensive research, development, and marketing strategies, Electromedical Technologies Inc aims to provide effective solutions while adhering to regulatory standards in the healthcare industry.
Sources:
Brainsway Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Brainsway Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
